Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts

Anna Maria Raiola, Alida Dominietto, Carmen di Grazia, Teresa Lamparelli, Francesca Gualandi, Adalberto Ibatici, Stefania Bregante, Maria Teresa Van Lint, Riccardo Varaldo, Anna Ghiso, Marco Gobbi, Angelo Michele Carella, Alessio Signori, Federica Galaverna, Andrea Bacigalupo

Research output: Contribution to journalArticlepeer-review


We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P

Original languageEnglish
Pages (from-to)1573-1579
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number10
Publication statusPublished - Oct 1 2014


  • Allogeneic transplant
  • Cord blood
  • Haploidentical
  • Unrelated

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)


Dive into the research topics of 'Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts'. Together they form a unique fingerprint.

Cite this